AVIR
Atea Pharmaceuticals, Inc.3.2200
+0.0700+2.22%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A reaffirms enrollment, commercial plans
Q&A largely reaffirmed prepared remarks on HCV Phase III timelines and HEV initiation, but management confidently confirmed cirrhotic enrollment targets for C-FORWARD after C-BEYOND success. Analysts grilled on commercial contracting across Medicare, Medicaid, and commercial channels; execs highlighted stable net pricing despite Epclusa dips, payer eagerness for formulary inclusion, and a balanced specialty market. They unpacked mITT endpoint flexibility to showcase potency amid variable adherence. Merck milestones hit in 2027 for ruzasvir. No walk-backs. Investors watch topline data midyear. Punchy: Targets locked in tight.
Key Stats
Market Cap
251.57MP/E (TTM)
-Basic EPS (TTM)
-1.77Dividend Yield
0%Recent Filings
8-K
Q4 results, HCV/HEV updates
Atea Pharmaceuticals reported Q4 and full-year 2025 results on March 5, 2026, with cash at $301.8M versus $454.7M year-end 2024 and net loss of $158.3M, up from $168.4M. HCV Phase 3 trials advanced, completing C-BEYOND enrollment with topline data mid-2026; HEV candidate AT-587 enters clinic mid-2026. Cash burn accelerates on HCV spend. Pipeline expands boldly.
10-K
FY2025 results
Atea Pharmaceuticals posted FY2025 operating expenses of $180.9M, down from $193.0M in FY2024, driven by $148.0M R&D (up slightly from $144.1M amid HCV Phase 3 ramp-up and $5M Merck milestone) yet offset by workforce cuts yielding $15M savings through 2027. Q4 spend skewed heavily to HCV trials and commercial manufacturing prep, with C-BEYOND fully enrolled (880+ patients) eyeing topline mid-2026 and C-FORWARD topline year-end 2026. Cash burned $132M operationally but ended at $301.8M, funding to NDA March 2027 sans revenue. $25M share repurchase wrapped Q3. HEV candidate AT-587 eyes Phase 1 mid-2026. Clinical delays from foreign sites or regulators could stall momentum.
8-K
Strong cash, HCV/HEV milestones
8-K
Q3 loss widens on HCV trials
Atea reported Q3 2025 net loss of $42M, with R&D expenses up to $38.3M from HCV Phase 3 ramp-up, cash at $329.3M. HCV trials C-BEYOND and C-FORWARD stay on track for mid-2026 topline; new data reveal bemnifosbuvir's dual mechanism against HCV. Pipeline expands to HEV with Phase 1 eyed mid-2026. Completed $25M buyback.
10-Q
Q3 FY2025 results
Atea trimmed operating losses in Q3 ended September 30, 2025, posting a $45.6M loss from operations (up 22.5% y/y from $37.2M) while YTD loss narrowed to $126.0M (down 18.2% y/y from $153.9M), driven by HCV external costs surging to $30.2M (up 252% y/y) after COVID spend cratered to $0.1M, offset by 35% lower G&A from reduced stock-based comp. Net loss hit $42.0M ($0.53/share) versus $31.2M ($0.37/share) y/y, narrowed by YTD $113.5M ($1.37/share, anti-dilutive shares excluded). Cash and marketable securities stood at $329.3M, funding HCV Phase 3 through 2027; completed $25M share repurchase. HCV enrollment advances in C-Beyond/C-Forward. Clinical trial delays could stall progress.
ABUS
Arbutus Biopharma Corporation
4.59-0.36
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
ATHA
Athira Pharma, Inc.
3.88+0.03
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
ATYR
aTyr Pharma, Inc.
0.73-0.00
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
HEPA
Hepion Pharmaceuticals, Inc.
0.07-0.01
NNVC
NanoViricides, Inc.
1.29+0.06
VIR
Vir Biotechnology, Inc.
6.48-0.24
VIRX
Viracta Therapeutics, Inc.
0.01+0.00